08:56 EST Rezolute (RZLT) down 88% at $1.27 in pre-market after ersodetug Phase 3 study data
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute’s Phase 3 study in congenital hyperinsulinism did not meet endpoints
- Rezolute files automatic mixed securities shelf
- Rezolute price target raised to $20 from $15 at Jefferies
- Rezolute Approves Key Proposals at Annual Meeting
- Promising Potential of Rezolute’s Ersodetug in Treating Congenital Hyperinsulinism Drives Buy Rating